Skip to main content
Adam Boruchov, MD, Oncology, New Milford, CT

AdamMBoruchovMD

Oncology • New Milford, CT

Hematologic Oncology

Senior Vice President, Chair of Cancer Institute Nuvance Health Professor, Medicine, University of Connecticut SOM

Join to view full profile

Dr. Boruchov is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Boruchov's full profile

Already have an account?

  • Office

    21 Elm St
    New Milford, CT 06776

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
  • State University of New York Downstate Medical Center College of Medicine
    State University of New York Downstate Medical Center College of MedicineClass of 1997

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2008 - 2025
  • NY State Medical License
    NY State Medical License 1998 - 2010
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Yale Researchers Say Customized Cancer Vaccine Shows Promise
    Yale Researchers Say Customized Cancer Vaccine Shows PromiseMay 20th, 2023
  • Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from Treatment
    Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
  • Nuvance Health Appoints Adam Boruchov, MD, System Chair of the Cancer Institute
    Nuvance Health Appoints Adam Boruchov, MD, System Chair of the Cancer InstituteOctober 26th, 2023

Grant Support

  • Targeting Fcrs On Dcs For Ag-Specific ToleranceNational Institute Of Allergy And Infectious Diseases2005–2008

Professional Memberships

Dr. Adam Boruchov, Dr. Adam Boruchov, MD, Dr. A Boruchov, Dr. Adam M Boruchov